215 related articles for article (PubMed ID: 11776157)
1. [Cytoreductive surgery in the management of stage IV epithelial ovarian cancer].
Zang R; Zhang Z; Chen J
Zhonghua Fu Chan Ke Za Zhi; 2000 Apr; 35(4):197-9. PubMed ID: 11776157
[TBL] [Abstract][Full Text] [Related]
2. Cytoreductive surgery for stage IV epithelial ovarian cancer.
Zang RY; Zhang ZY; Cai SM; Li ZT; Chen J; Tang MQ; Liu Q
J Exp Clin Cancer Res; 1999 Dec; 18(4):449-54. PubMed ID: 10746968
[TBL] [Abstract][Full Text] [Related]
3. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.
Bristow RE; Montz FJ; Lagasse LD; Leuchter RS; Karlan BY
Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096
[TBL] [Abstract][Full Text] [Related]
4. [Treatment and prognostic factors for stage IV epithelial ovarian cancer].
Wu M; Shen K; Lang J
Zhonghua Fu Chan Ke Za Zhi; 2000 Apr; 35(4):200-3. PubMed ID: 11776158
[TBL] [Abstract][Full Text] [Related]
5. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer.
Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Levine DA; Poynor EA; Aghajanian C; Jarnagin WR; DeMatteo RP; D'Angelica MI; Barakat RR; Chi DS
Gynecol Oncol; 2006 Dec; 103(3):1083-90. PubMed ID: 16890277
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors of stage IV epithelial ovarian cancer: a multicenter retrospective study.
Akahira JI; Yoshikawa H; Shimizu Y; Tsunematsu R; Hirakawa T; Kuramoto H; Shiromizu K; Kuzuya K; Kamura T; Kikuchi Y; Kodama S; Yamamoto K; Sato S
Gynecol Oncol; 2001 Jun; 81(3):398-403. PubMed ID: 11371128
[TBL] [Abstract][Full Text] [Related]
7. Impact of secondary cytoreductive surgery on survival of patients with advanced epithelial ovarian cancer.
Zang RY; Zhang ZY; Li ZT; Cai SM; Tang MQ; Chen J; Liu Q
Eur J Surg Oncol; 2000 Dec; 26(8):798-804. PubMed ID: 11087649
[TBL] [Abstract][Full Text] [Related]
8. [Clinical significance of secondary cytoreductive surgery for recurrent advanced ovarian cancer].
Zang R; Zhang Z; Cai S
Zhonghua Zhong Liu Za Zhi; 2002 Mar; 24(2):194-6. PubMed ID: 12015048
[TBL] [Abstract][Full Text] [Related]
9. The role of secondary cytoreductive surgery for recurrent mucinous epithelial ovarian cancer (mEOC).
Cheng X; Jiang R; Li ZT; Tang J; Cai SM; Zhang ZY; Tian WJ; Zang RY
Eur J Surg Oncol; 2009 Oct; 35(10):1105-8. PubMed ID: 19443175
[TBL] [Abstract][Full Text] [Related]
10. Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits?
Zang RY; Li ZT; Tang J; Cheng X; Cai SM; Zhang ZY; Teng NN
Cancer; 2004 Mar; 100(6):1152-61. PubMed ID: 15022281
[TBL] [Abstract][Full Text] [Related]
11. The role of cytoreductive surgery in the management of stage IV uterine papillary serous carcinoma.
Bristow RE; Duska LR; Montz FJ
Gynecol Oncol; 2001 Apr; 81(1):92-9. PubMed ID: 11277657
[TBL] [Abstract][Full Text] [Related]
12. [Factors affecting disease recurrence and the role of secondary therapies in the management for patients with recurrent ovarian carcinoma].
Zang R; Zhang Z; Cai S
Zhonghua Fu Chan Ke Za Zhi; 2002 Sep; 37(9):546-9. PubMed ID: 12411017
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of residual disease in patients with stage IV epithelial ovarian cancer.
Munkarah AR; Hallum AV; Morris M; Burke TW; Levenback C; Atkinson EN; Wharton JT; Gershenson DM
Gynecol Oncol; 1997 Jan; 64(1):13-7. PubMed ID: 8995541
[TBL] [Abstract][Full Text] [Related]
14. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma.
Chi DS; McCaughty K; Diaz JP; Huh J; Schwabenbauer S; Hummer AJ; Venkatraman ES; Aghajanian C; Sonoda Y; Abu-Rustum NR; Barakat RR
Cancer; 2006 May; 106(9):1933-9. PubMed ID: 16572412
[TBL] [Abstract][Full Text] [Related]
15. Effect of retroperitoneal lymphadenectomy on prognosis of patients with epithelial ovarian cancer.
Wang Z; Xiong Z; Wang S
Chin Med J (Engl); 2003 Apr; 116(4):588-92. PubMed ID: 12875728
[TBL] [Abstract][Full Text] [Related]
16. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
[TBL] [Abstract][Full Text] [Related]
17. Does debulking surgery improve survival in biologically aggressive ovarian carcinoma?
Le T; Krepart GV; Lotocki RJ; Heywood MS
Gynecol Oncol; 1997 Nov; 67(2):208-14. PubMed ID: 9367710
[TBL] [Abstract][Full Text] [Related]
18. Effect of surgical debulking on survival in stage IV ovarian cancer.
Liu PC; Benjamin I; Morgan MA; King SA; Mikuta JJ; Rubin SC
Gynecol Oncol; 1997 Jan; 64(1):4-8. PubMed ID: 8995539
[TBL] [Abstract][Full Text] [Related]
19. Surgical treatment of diaphragm disease correlates with improved survival in optimally debulked advanced stage ovarian cancer.
Aletti GD; Dowdy SC; Podratz KC; Cliby WA
Gynecol Oncol; 2006 Feb; 100(2):283-7. PubMed ID: 16182350
[TBL] [Abstract][Full Text] [Related]
20. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study.
Eisenkop SM; Friedman RL; Wang HJ
Gynecol Oncol; 1998 May; 69(2):103-8. PubMed ID: 9600815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]